1. Home
  2. ADAP vs SPE Comparison

ADAP vs SPE Comparison

Compare ADAP & SPE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADAP
  • SPE
  • Stock Information
  • Founded
  • ADAP 2008
  • SPE 1993
  • Country
  • ADAP United Kingdom
  • SPE United States
  • Employees
  • ADAP N/A
  • SPE N/A
  • Industry
  • ADAP Biotechnology: Pharmaceutical Preparations
  • SPE Finance/Investors Services
  • Sector
  • ADAP Health Care
  • SPE Finance
  • Exchange
  • ADAP Nasdaq
  • SPE Nasdaq
  • Market Cap
  • ADAP 158.6M
  • SPE 167.3M
  • IPO Year
  • ADAP 2015
  • SPE N/A
  • Fundamental
  • Price
  • ADAP $0.56
  • SPE $15.48
  • Analyst Decision
  • ADAP Strong Buy
  • SPE
  • Analyst Count
  • ADAP 4
  • SPE 0
  • Target Price
  • ADAP $2.79
  • SPE N/A
  • AVG Volume (30 Days)
  • ADAP 623.5K
  • SPE 25.4K
  • Earning Date
  • ADAP 03-05-2025
  • SPE 01-01-0001
  • Dividend Yield
  • ADAP N/A
  • SPE 8.55%
  • EPS Growth
  • ADAP N/A
  • SPE N/A
  • EPS
  • ADAP N/A
  • SPE N/A
  • Revenue
  • ADAP $175,041,000.00
  • SPE N/A
  • Revenue This Year
  • ADAP $204.91
  • SPE N/A
  • Revenue Next Year
  • ADAP N/A
  • SPE N/A
  • P/E Ratio
  • ADAP N/A
  • SPE N/A
  • Revenue Growth
  • ADAP 146.27
  • SPE N/A
  • 52 Week Low
  • ADAP $0.53
  • SPE $10.26
  • 52 Week High
  • ADAP $2.05
  • SPE $12.59
  • Technical
  • Relative Strength Index (RSI)
  • ADAP 40.12
  • SPE 55.26
  • Support Level
  • ADAP $0.55
  • SPE $15.41
  • Resistance Level
  • ADAP $0.61
  • SPE $15.75
  • Average True Range (ATR)
  • ADAP 0.03
  • SPE 0.20
  • MACD
  • ADAP -0.00
  • SPE -0.02
  • Stochastic Oscillator
  • ADAP 12.14
  • SPE 38.10

About ADAP Adaptimmune Therapeutics plc

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.

About SPE Special Opportunities Fund Inc

Special Opportunities Fund Inc is the United States based closed-ended diversified management investment company. Its investment objective is to have the total return. The company's investment portfolio consists of investment companies, common stocks, money market funds, commodity partnerships, preferred stocks, convertible bonds, liquidating trusts, promissory notes, senior unsecured notes, warrants, rights, corporate notes and corporate bonds. In addition, it also makes investments in construction materials, consumer finance, healthcare equipment and supplies, independent power and renewable electricity producers, insurance, personal products, professional services and real estate investment trusts.

Share on Social Networks: